Expediting MRI-Based Proof-of-Concept Stroke Trials Using an Earlier Imaging End Point | Zendy

Martin Ebinger | Zendy; Hanne Christensen | Zendy; Deidre Anne De Silva | Zendy; Mark Parsons | Zendy; Christopher Levi | Zendy; Kenneth Butcher | Zendy; Christopher F. Bladin | Zendy; P. Alan Barber | Zendy; Geoffrey A. Donnan | Zendy; Stephen M. Davis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Expediting MRI-Based Proof-of-Concept Stroke Trials Using an Earlier Imaging End Point

Author(s) -

Martin Ebinger,

Hanne Christensen,

Deidre Anne De Silva,

Mark Parsons,

Christopher Levi,

Kenneth Butcher,

Christopher F. Bladin,

P. Alan Barber,

Geoffrey A. Donnan,

Stephen M. Davis

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.532622

Subject(s) - medicine , interquartile range , thrombolysis , lesion , placebo , stroke (engine) , tissue plasminogen activator , magnetic resonance imaging , clinical endpoint , fibrinolytic agent , nuclear medicine , clinical trial , radiology , surgery , pathology , myocardial infarction , mechanical engineering , alternative medicine , engineering

Before Phase III trials of acute stroke therapies, proof-of-concept MRI trials are increasingly used to gauge the likelihood of success. Given that animal models use infarct volume as the end point, Phase II trials have aimed to translate the findings using infarct growth. These trials could be expedited if subacute diffusion-weighted imaging lesion volume replaced late T2-weighted lesion volume as the primary end point.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research